TPST Tempest Therapeutics: Price-to-Projected Revenue Ratio
The projected P/S dynamics reflect market revenue expectations, where represents the current level of the metric. Tempest Therapeutics (TPST) is preparing large-scale Phase III trials for liver cancer therapy, attracting biopharmaceutical partners. Market capitalization growth is driven by the success of the drug TPST-1495 and interest from industry behemoths. Development is led by an elite staff of chemists and oncologists motivated by stock option programs.
Analytical breakdowns for Tempest Therapeutics
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Tempest Therapeutics|TPST - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Tempest Therapeutics|TPST - Company Cumulative Indebtedness|Debt to Book Value Tempest Therapeutics Corp|TPST - Company Long-Term Loans and Borrowings|Company Current Liabilities Tempest Therapeutics|Quick Ratio tempesttx.com
- business earnings and investment ratios data:
TPST - Final Profit|Projected Future Earnings Tempest Therapeutics|TPST - Market Cap to Earnings|Future Price to Earnings Tempest Tx|TPST - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Tempest Therapeutics Corp|TPST - Operating profit EBITDA|Earnings per share for the last twelve months Tempest Therapeutics|TPST - Earnings per one share for the last 12 months|Quarterly EPS earnings growth tempesttx.com|TPST - Earnings per share growth rate in current year|Expected earnings per share growth for next year Tempest Therapeutics
- sales volume and revenue information:
General company analysis:Tempest Therapeutics, Inc. (TPST)
For Tempest Therapeutics (TPST), whose capitalization relies on future royalties from liver cancer therapy, the forward P/S history reflects market expectations regarding revenue scalability. The current value of shows a premium to expected sales, allowing investors to assess the fairness of the business valuation relative to the projected market share capture without waiting for quarterly reports.
Key competitors
Forward P/S Multiple ONC (BeiGene)|Halozyme Therapeutics, Inc. (HALO) - Market Cap to Future Revenue Ratio|RVMD - Price-to-Projected Revenue Ratio|Ascentage Pharma Corp (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology, Inc. (CGON) - Price-to-Projected Revenue Ratio|Future Price to Revenue URGN (urogen.com)|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Personalis Inc PSNL|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|Market Cap to Expected Sales Ratio Delcath Corp|Y-mAbs Therapeutics - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio AURA (aurabiosciences.com)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc)|SLS (sellaslifesciences.com) - Forward Price-to-Revenue Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|HURA: Forward Price to Sales|Forward P/S Multiple TARA|FATE - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|Forward Price to Sales TCRX|Champions Oncology Corp - Forward P/S Multiple|XBIT - Forward P/S Multiple|cel-sci.com (CVM) - Price-to-Projected Revenue Ratio|Future Price to Revenue OSTX (OS Therapies Inc.)|RADX (Radiopharm Theranostics Limited) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Artiva ARTV|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Ltd.)|Forward P/S Multiple verupharma.com (VERU)|Xilio Therapeutics - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio RENB (Renovaro Biosciences)|Mural Bio - Forward P/S Multiple|Market Cap to Expected Sales Ratio Kairos Pharma Ltd KAPA|OKUR: Forward P/S Multiple|Forward Price-to-Revenue Multiple CytoMed Therapeutics Limited|Price-to-Projected Revenue Ratio Curis Inc.|Apollomics Corp (APLM) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple THAR (Tharimmune Corp)|Price to Expected Revenue Ratio ADVB|Price-to-Projected Revenue Ratio Genprex, Inc. GNPX|CLDI (Calidi Biotherapeutics Inc.) - Future Price to Revenue|SBFM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Xenetic Biosciences XBIO|SLRX (Salarius) - Forward Price-to-Revenue Multiple|PPBT: Price to Expected Revenue Ratio|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple beigene.com (BGNE)|Forward P/S Multiple CKPT|Forward P/S Multiple elevationoncology.com (ELEV)|Price-to-Projected Revenue Ratio iCAD ICAD|IKNA: Market Cap to Projected Revenue|Notable Labs, Ltd. - Forward P/S Multiple|Viracta Therapeutics (VIRX) - Forward Price-to-Revenue Multiple|MOR: Forward P/S Multiple|Market Cap to Future Revenue Ratio NAYA Biosciences Inc (NAYA)|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd
